Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, bringing the FDA-approved Enbumyst nasal spray into its cardiovascular portfolio. This first-in-class nasal spray loop diuretic helps manage fluid retention for congestive heart failure, marking a new step in Esperion’s plan to address the growing global burden of cardiometabolic disease. Executives anticipate that Enbumyst will bolster the company’s commercial capabilities and revenue growth.
Subscribe
Chronic Illness Management
Industry News
Mergers and Acquisitions
Therapy Options
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with EnbumystTM (bumetanide nasal spray)
Photo by Benzinga
Key Takeaways:
- Esperion completes acquisition of Corstasis to enhance its cardiovascular franchise
- Enbumyst becomes the first FDA-approved nasal spray loop diuretic on the market
- The product treats edema associated with congestive heart failure, hepatic, and renal disease in adults
- Esperion plans commercial synergy by leveraging its established infrastructure
- Company leadership forecasts continued revenue growth in alignment with its Vision 2040
Esperion Acquires Corstasis
Esperion Therapeutics (NASDAQ: ESPR) has announced the closing of its acquisition of Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company dedicated to advancing outpatient therapies for edema linked to cardiovascular, hepatic, and renal conditions. The move is designed to broaden Esperion’s cardio-focused offerings while addressing the global rise in cardiometabolic disease.
A Breakthrough in Fluid Management
Enbumyst (bumetanide nasal spray)—the cornerstone therapy developed by Corstasis—earned Food and Drug Administration (FDA) approval in September 2025. As the first and only nasal spray loop diuretic, Enbumyst offers a novel option for adults managing fluid retention arising from congestive heart failure (CHF), as well as hepatic and renal disorders. “Enbumyst is a novel, patient-friendly option that we believe can meaningfully improve fluid management for congestive heart failure patients,” says Sheldon Koenig, President and Chief Executive Officer of Esperion.
Commercial Integration and Synergy
With Enbumyst now in its arsenal, Esperion plans to utilize its robust commercial infrastructure, including prescriber outreach and payer engagement, to expedite awareness and adoption of this category-first innovation. Company leadership expects this product to boost both patient access and adherence by offering a more convenient route of administration—an advantage critical in outpatient care.
Addressing the Global Cardiometabolic Challenge
By adding Enbumyst to its portfolio, Esperion strengthens its position in the fight against cardiometabolic diseases. This acquisition supports Esperion’s Vision 2040, which emphasizes developing differentiated therapies to alleviate the expanding worldwide burden of heart and metabolic conditions. Officials at Esperion point to Enbumyst’s novel features as a prime example of the sort of advanced solutions needed in frontline cardiometabolic care.
Looking Ahead
Along with reinforcing Esperion’s commercial leverage, the Enbumyst nasal spray is expected to foster sustained revenue growth. Executives remain optimistic about its many advantages, from the straightforward administration route to the broadened patient base ready for a new treatment option. This step not only fulfills Esperion’s commitment to accessible,-effective therapy but also marks a milestone on the company’s longer-term path to lead in cardiometabolic risk management.
